Dalton Pharma Services Expands its Contract Analytical Services
"Our commitment to accelerate the drug discovery and development process continues as we add to our state-of-the-art instrumentation to support GMP API synthesis, sterile dose formulation and sterile fill, method validation and other outsourced analytical projects including stability studies, bioanalytical development and analysis," said Peter Pekos, President and CEO. Dalton continues to develop and grow its analytical capabilities to enhance it's commitment to quality, responsiveness, flexibility and innovation through the supply of unparalleled contract pharmaceutical development services.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.